Catlett et al v. McKesson Corporation et al

Filing 25

ORDER GRANTING MOTION TO REMAND AND DENYING MOTION TO STAY by Judge William Alsup [denying 11 Motion to Stay; granting 12 Motion to Remand]. (whasec, COURT STAFF) (Filed on 8/23/2013)

1
2
3
4
5
6
7

IN THE UNITED STATES DISTRICT COURT

8

FOR THE NORTHERN DISTRICT OF CALIFORNIA

9

11
For the Northern District of California

United States District Court

10
DEADRA CATLETT, et al.,

13

No. C 13-03067 WHA

Plaintiffs,

12
v.

16

MCKESSON CORPORATION, a
California corporation, SMITHKLINE
BEECHAM CORPORATION d/b/a/
GLAXOSMITHKLINE LLC, a
corporation, and DOES 1–100, inclusive,

17

Defendants.

14
15

ORDER GRANTING MOTION
TO REMAND AND
DENYING MOTION TO STAY

/
18
INTRODUCTION

19
20

In this pharmaceutical products-liability action, plaintiffs move to remand to state court

21

for lack of federal jurisdiction while defendants move to stay all proceedings pending potential

22

transfer to an MDL. For the reasons stated below, plaintiffs’ motion to remand is GRANTED and

23

defendants’ motion to stay is DENIED.

24
25

STATEMENT
Plaintiffs filed a complaint in the Superior Court of the State of California for the County

26

of San Francisco in June 2013 for alleged injuries from the use of Avandia, a prescription

27

pharmaceutical used to treat type-2 diabetes. Among other defendants, plaintiffs filed suit

28

against McKesson Corporation, a California-based pharmaceutical distributor. Defendant

1

GlaxoSmithKline LLC removed the action to federal court on fraudulent joinder grounds and

2

moved to stay this action pending transfer to the Avandia MDL in the United States District

3

Court for the Eastern District of Pennsylvania. Plaintiffs then filed a motion to remand, arguing

4

that this Court should first consider the merits of its motion before entertaining any stay of these

5

proceedings.

6

This order follows full briefing and oral argument.

7
8
9

ANALYSIS
Our court of appeals has not yet addressed whether courts must first decide the merits
of a motion to remand before determining whether to stay the proceedings. Generally speaking,
a stay is warranted if this would serve judicial economy. See, e.g., In re Iphone Application

11
For the Northern District of California

United States District Court

10

Litig., No. 10-5878, 2011 WL 2149102, at *2 (N.D. Cal. May 31, 2011) (Judge Lucy Koh).

12

In similar actions involving Avandia, courts in this district have granted a stay. Those courts

13

found that doing so would promote judicial economy because the MDL judge has addressed

14

issues of “fraudulent joinder, fraudulent misjoinder of plaintiffs, the forum defendant rule, and

15

questions relating to removal by defendants who have not yet been served.” See, e.g., Poff v.

16

McKesson, No. 13-3115, 2013 WL 3949207, at *2 (N.D. Cal. July 30, 2013) (Judge Jeffrey

17

White); see also Flores v. McKesson, No. 13-3153 (N.D. Cal. Aug. 2, 2013) (Judge Jon Tigar);

18

Alvarez v. McKesson, No. 13-3112 (N.D. Cal. July 24, 2013) (Judge Thelton Henderson).

19

Given, however, the circumstances of the instant action, namely that the MDL has already

20

remanded similar actions because it found that McKesson had not been fraudulently joined, this

21

order finds differently.

22

The question of whether a motion to stay, pending transfer to an MDL, should be decided

23

before a motion to remand occurs frequently. It is best to rule in the way that most furthers

24

judicial economy, unless this would unreasonably prejudice one of the parties. Thus, when a

25

jurisdictional issue has not yet arisen before the MDL, a motion to stay has been denied and the

26

action remanded to state court because burdening the MDL with a new jurisdictional issue would

27

not be in the interest of judicial economy. Marble v. Organon, No. 12-2213, 2012 WL 2237271,

28

at *3 (N.D. Cal. June 15, 2012). Where, however, other cases pending before the MDL have
2

1

raised the same jurisdictional issue, a stay was granted because it would be in the interest of

2

judicial economy to have all these issues decided together. See, e.g., Addison v. Bristol-Meyers

3

Squibb Co., No. 13-2166, 2013 WL 3187859, at *1 (N.D. Cal. June 21, 2013).

4

Here, the MDL has already ruled on the jurisdictional issue at stake. The MDL found

5

that “McKesson is not fraudulently joined as a defendant in this action . . . such that remand is

6

required both pursuant to the forum defendant rule and for lack of subject matter jurisdiction.”

7

In re Avandia, 624 F. Supp. 2d 396, 421 (E.D. Pa. 2009) (Judge Cynthia Rufe). Under these

8

circumstances, judicial economy would not be served by a transfer to the MDL only to have the

9

MDL court remand the action back to state court.
GSK submits that upon its information and belief, McKesson had not been served with

11
For the Northern District of California

United States District Court

10

the complaint on the date it removed the case (Dkt. No. 1 at 4). Not so. Plaintiffs’ supplemental

12

briefing shows that McKesson was served with the complaint on July 2, 2013, the day of

13

removal. MDL Judge Cynthia Rufe has already found that in this specific fact pattern, a remand

14

is proper: “the case was removed from California court after McKesson was properly joined

15

and served, and hence in violation of the forum defendant rule.” In re Avandia, 624 F. Supp. 2d

16

at 421.

17

GSK’s removal in violation of the forum defendant rule alone is sufficient basis to grant a

18

remand. The forum defendant rule states that “a civil action otherwise removable . . . may not be

19

removed if any of the parties in interest properly joined and served as defendants is a citizen of

20

the State in which such action is brought.” 28 U.S.C. 1441(b)(2). Removal would only have

21

been proper if GSK had been served before McKesson, the forum defendant. In the present

22

action, however, GSK removed after McKesson was served. As noted above, MDL Judge

23

Cynthia Rufe has already held that this constitutes improper removal and GSK has failed to

24

show any likelihood that she may now rule differently.

25

GSK nonetheless raises three arguments in support of its motion to stay. It argues that

26

McKesson has been fraudulently joined in this action because (1) no viable claim can be stated

27

against McKesson and (2) since 2009, no action was allegedly taken against McKesson in the

28

proceedings previously remanded by MDL Judge Cynthia Rufe. It also argues that (3) there is
3

1

federal jurisdiction under CAFA. Even assuming, arguendo, that GSK could remove the action

2

despite the forum defendant rule, these arguments fail to persuade for the following reasons.

3

First, GSK argues that plaintiffs can state no viable claim against McKesson. During

4

oral argument, counsel for GSK supported this argument by citing Brown v. Superior Court, 44

5

Cal. 3d 1049 (1988). That decision concerned product liability for manufacturers of

6

pharmaceuticals. Under California law, however, distributors can also be liable for design

7

defects. Vandermark v. Ford Motor Co., 61 Cal. 2d 256, 262–263 (1964). It is thus plausible

8

that plaintiffs may have a claim against McKesson. GSK failed to cite any binding authority to

9

the contrary.
This conclusion is not altered by the Supreme Court’s decision in PLIVA, Inc. v.

11
For the Northern District of California

United States District Court

10

Mensing, 131 S. Ct. 2567 (2011). According to GSK, that decision preempts any state-law claim

12

plaintiffs may have against McKesson, meaning McKesson was fraudulently joined in this

13

action. Not so. A preemption defense goes to the merits of a plaintiff’s case and cannot

14

overcome the strong presumption against removal jurisdiction. Hunter v. Philip Morris USA,

15

582 F.3d 1039, 1045 (9th Cir. 2009). GSK failed to cite any binding authority that would

16

suggest otherwise.

17

Second, GSK contends that McKesson was fraudulently joined because in the actions

18

previously remanded by MDL Judge Cynthia Rufe, allegedly no action was taken against

19

McKesson. The removal took place over four years ago and since then, GSK contends, the

20

plaintiffs in those actions have not actively pursued any claims against McKesson. GSK argues

21

this shows that McKesson has been fraudulently joined in the present action. This argument,

22

too, must be rejected. During oral argument, counsel for plaintiffs disputed GSK’s allegation

23

that no action was taken against McKesson in those actions. But even if GSK’s contention were

24

true, that does not alter the conclusion for this action. The fact that no action was taken against

25

McKesson in separate litigation, involving different plaintiffs and different counsel, cannot lead

26

to the conclusion that McKesson, against which plaintiffs may have an otherwise viable claim,

27

was fraudulently joined in this action.

28
4

1

Third, GSK contends that there is removal jurisdiction under CAFA in this action, an

2

issue not yet addressed by MDL Judge Cynthia Rufe. But removal of a mass action under

3

CAFA requires that the action involves at least 100 plaintiffs. 28 U.S.C. 1332(d)(11)(B)(I).

4

That requirement is not met in the present action. Furthermore, Section 1332(d)(11)(c) explicitly

5

precludes transfer of mass actions, removed pursuant to CAFA, to an MDL unless a majority of

6

the plaintiffs request such transfer. Even if the action were removable under CAFA, GSK’s

7

motion to stay would therefore still be denied.

8

This order is not persuaded by GSK’s contention that it would suffer prejudice if a stay is

is improper. To the contrary, it would cause undue prejudice to plaintiffs to be forced to file and

11
For the Northern District of California

denied when it removed the action from state court despite the MDL’s ruling that such removal

10

United States District Court

9

argue motions to remand in two different courts before being sent back to square one — state

12

court, where this action belongs.

13
14

CONCLUSION
GSK will not be granted a stay since the MDL has already made clear this action should

15

be remanded. GSK’s motion to stay is therefore DENIED and plaintiffs’ motion to remand is

16

GRANTED. The Clerk shall REMAND this action to the Superior Court for the County of

17

San Francisco.

18
19

IT IS SO ORDERED.

20
21
22

Dated: August 23, 2013.

WILLIAM ALSUP
UNITED STATES DISTRICT JUDGE

23
24
25
26
27
28
5